Therapia Hungarica (English edition)最新文献

Tri Regol has been used as a contraceptive during 541 cycles of 108 women and in further 73 cases for normalizing cycle anomalies or improving tablet tolerance. Pregnancy did not occur. The side-effects were insignificant. The triphasic therapy proved to be effective in all three fields. The author has mentioned the critical attitude towards oral contraceptives and calls the attention to the importance of an objective evaluation of the usefulness of these tablets. He emphasizes that the use of the multiphasic, low-dose pills is at present most up-to-date contraceptive method.

The follicle maturation influencing effect of Clostilbegyt (50 mg Clomiphene-citrat) has been examined in 30 women suffering from primary or secondary sterility. For monitoring follicular development a vaginal ultrasound scanner was used. The development of yellow body and its adequate function have been controlled with serum progesterone determination. In the first therapeutical cycle daily 1 tbl. Clostilbegyt was used from the 4th day of the menstruation in a five day period. In the next cycle daily 2 tbl. were administered similarly. If the therapy was unsuccessful, then 3 tbl. per day Clostilbegyt was used as treatment in the 3rd cycle. In the course of monitoring with vaginal ultrasound scanner successful ovulation induction has been proved in 80% of the Clostilbegyt treated cases (in 24 of 30 cases). During the examination period pregnancy occurred in 7 cases (29.2%). Vaginal ultrasound monitoring is recommended by the author for ovulation induction therapy.

Norcuron injection has been applied for the prolongation of the duration of muscle relaxing action of Arduan in 104 patients. The patients underwent major surgery and 1/5 of them were of advanced age. Neuromuscular blockade could be prolonged for the required duration of operation with lower doses of Norcuron (2 mg, 1 mg) than the currently used ones. For avoiding eventual cumulation or synergism the repetition of lower doses to meet the requirements seems to be the most advantageous method.

The changes of "E" and "A" waves of mitral inflow have been measured before, and 1,2,3,5 and 10 minutes after the use of Nitromint spray (EGIS) in coronary disease patients (14 cases), and in patients who had undergone bypass surgery (7 cases), by pulsatile wave Doppler's echocardiography. The "E" wave gave more information on the preload decreasing effect of the drug, than the "A" wave (significant decrease in minutes 1,2,3,5 and 10 following spraying). On the basis of the changes of the "E" wave compared in the two patient groups a difference in the responses to Nitromint spray could be revealed: the non-operated coronary disease patients responded with a more marked decrease of preload to Nitromint spray than the revascularize patients.

A retrospective therapeutical follow-up of 64 therapy-resistant epileptics treated by phenitoin (DPH) is made chronically. In the study 232 treatment periods of at least two years' duration were analyzed. Distribution of DPH therapeutic combinations was evaluated according to the type of epilepsy, seizure form, seizure frequency, elements of patient compliance, and results of serum level measurements. According to the author's opinions DPH is still one of the most effective agents in the treatment of resistant epilepsy, but in most cases as a constant component of antiepileptic bitherapy. Its pharmacokinetic features and optimal dosage show great individual variability, larger than that of other drugs and, in cases of combined drug regimens, interactions may more frequently be expected.

The effect of Paxirasol nasal spray (EGIS) has been examined in 25 patients following open heart surgery. In 18 of the patients increased secretion, in 7 crusting due to dryness of mucosa were observed as accompanying symptoms. These symptoms ceased in response to Paxirasol therapy, in the former cases within one week, in the latter ones within two weeks. The drug was applied in daily 3-5 times 1-mg (3-5 x 5 puffs) doses.

Tri-Regol, a triphasic oral contraceptive tablet, has been used by 52 young and premenopausal fertile women during 189 cycles. Pregnancy was not observed, complication did not occur, none of the women discontinued the treatment because of health reasons. The women of both borderline age groups tolerated the tablet well which even exerted a therapeutic effect by controlling partly puberal cycle anomalies, partly premenopausal complaints. According to the author's opinion Tri-Regol is a valuable contraceptive for borderline age groups and may be useful as hormone therapy in certain cases.

Domperidone has been used as a gastrokinetic and anti-emetic drug within the frames of an intensive care programme in 57 patients with a history of 3-4 days of acute myocardial infarction. According to the observations, Motilium prevents the development of gastroduodenal complaints and nausea, vomiting in a period following the first days of acute therapy and promotes the start of bowel movement and defecation. It has no cardiac or other toxic effects and does not influence the action of other drugs.

The author processed in the form of a literary analysis the results of the clinical studies performed with Tri-Regol tablet so far. Within this scope he discusses the contraceptive effect, the tolerance of the women, the therapeutical use, the possibility of managing intolerance to other tablets, and some other matters of detail. He reviews the basic principles and the mechanism of action of triphasic treatment. He demonstrates the importance of contraception by demographical data too.